SZD.F Santen Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
11.10 EUR
Close of Nov 12, 2026
8.15 11.75
Market cap
EUR 3.57B
P/E
16.8x
P/B
2.06x
ROE
10.2%
Dividend yield
2.12%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is SZD.F undervalued?

Graham number
Price11.10
Graham value8.94
Premium24.1%

SZD.F trades 24.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Santen Pharmaceutical Co. Ltd fundamental analysis

No fundamental analysis for Santen Pharmaceutical Co. Ltd yet.

Santen Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Santen Pharmaceutical Co. Ltd

Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocula…

Full company profile